PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California, Inc. Announces Rescheduling of 2020 Annual Meeting of Stockholders and Move to Virtual Meeting

Pacific Biosciences of California, Inc. Announces Rescheduling of 2020 Annual Meeting of Stockholders and Move to Virtual Meeting

MENLO PARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) has announced that it is rescheduling the date of the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) previously scheduled for Thursday, June 18, 2020, to Tuesday, August 4, 2020, at 9:00 a.m., Pacific Time, and  changing  the format to a virtual meeting in light of the continuing public health impact of the COVID-19 pandemic. In connection with the change of the Annual Meeting date, the record date for determining stockholders entitled to attend and vote at the Annual Meeting has been changed to 5:00 p.m. Pacific Time on Monday, June 15, 2020.

Furthermore, the Company will be revising its proposal to stockholders to approve the Company 2020 Equity Incentive Plan and would like to provide additional time for stockholders to review, consider and cast their vote on the revised proposal. There are no changes to the other proposals previously described in the Company’s proxy statement for the Annual Meeting. The Company will be distributing a proxy statement, proxy card and notice of internet availability for the Annual Meeting describing the proposals to be voted upon. Stockholders who have previously sent in proxies, or voted by telephone or by Internet, will be asked to submit new proxies or vote by telephone or Internet in advance of the meeting on August 4, 2020 by one of the methods described in the proxy statement to be distributed.

Stockholder proposals intended for inclusion in the Company’s definitive proxy statement for the Annual Meeting pursuant to Rule 14a-8 must be received by the Company’s Corporate Secretary at  no later than 5:00 p.m. Pacific time on June 18, 2020 (which the Company believes is a reasonable time before it begins to print and send its proxy materials).

To be admitted to the virtual Annual Meeting, stockholders will need to register at and enter certain information, including their name and the 15-digit control number found on the proxy card, voting instruction form, or notice of internet availability to be distributed stockholders, by following the instructions available on the meeting website.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) sequencing technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT® Sequencing.

Contacts

Trevin Rard

650.521.8450

EN
08/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

 PRESS RELEASE

PacBio Enters High-Throughput Carrier Screening Market with Standalone...

PacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screening MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the high-throughput carrier screening market with a significantly expanded and enhanced suite of PureTarget products. The updated solutions leverage PacBio’s highly ...

 PRESS RELEASE

PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomic...

PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer MENLO PARK, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that EpiCypher, a recognized leader in epigenetics tools, has joined the PacBio Compatible program. The partnership brings EpiCypher’s CUTANA® Hia5 enzy...

 PRESS RELEASE

PacBio Announces Second Quarter 2025 Financial Results

PacBio Announces Second Quarter 2025 Financial Results MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results:  Q2 2025Q2 2024Revenue$39.8 million$36.0 millionInstrument revenue$14.2 million$14.7 millionConsumable revenue$18.9 million$17.0 millionService and other revenue$6.7 million$4.3 millionRevio™ systems1524Vega™ systems38—Annualized Revio pull-through per system~$219,000~$251,000Cash, cash equivalents, and investments$314.7 million$509.8 million Gross margin, operating...

 PRESS RELEASE

PacBio to Present at Upcoming Investor Conferences

PacBio to Present at Upcoming Investor Conferences MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 2:30 PM ET in Boston, MAMorgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 12:20 PM ET in New York, NY Live webcasts of the events can be accessed at the company’s in...

 PRESS RELEASE

Nature Methods Paper Leverages PacBio Sequencing Technology to Develop...

Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools MENLO PARK, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of describing a new, comprehensive truth-set of genomic variation whi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch